Different Doses of Oral Melatonin Supplements in Chronic Kidney Disease (CKD)-Associated Sleep Disorders

Status unconfirmed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: End Stage Renal Disease, Chronic Kidney Disease, Sleep Disorder

In brief

The study will evaluate the safety and efficacy of melatonin supplementation in CKD and ESRD patients with sleep disorders to reduce sleep latency times, the number of apnea/hypopneic episodes, and prolong duration in rapid eye movement (REM) sleep in CKD and ESRD patients with sleep disordered breathing.

Key facts

Study ID
NCT01922999
Run by
Southeast Renal Research Institute
People needed
53
Starts
2012-12-01
Expected to finish
2017-12-01
Last updated by the study team
2017-01-24

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.